Daily BriefsHealthcare

Daily Brief Health Care: Tokyo Stock Exchange Tokyo Price Index Topix, Regeneron Pharmaceuticals and more

In today’s briefing:

  • Companies Should Communicate Their Human Resources Strategy Rather than Detailed Disclosure Rules
  • Regeneron Pharmaceuticals: The Libtayo Stake Acquisition & Other Driver

Companies Should Communicate Their Human Resources Strategy Rather than Detailed Disclosure Rules

By Aki Matsumoto

  • Companies had expected detailed rules, as with various disclosure documents, but was puzzled by government’s guidelines, which were conceptual and didn’t provide guidance on what to disclose and how much.
  • It is likely that the disclosure in annual securities reports, which are legal documents, will fill the space by disclosing items that are specifically identified and easy to show quantitatively.
  • Companies that cannot clearly explain their policies on investment in human capital and human resource strategies in their management strategies are unlikely to attract human resources.

Regeneron Pharmaceuticals: The Libtayo Stake Acquisition & Other Driver

By Baptista Research

  • Regeneron had a successful second quarter surpassing Wall Street expectations on all counts with noteworthy performance in every segment.
  • The company made considerable pipeline progress in addition to having good commercial execution, with 3 regulatory approvals, 2 accepted regulatory filings, and 1 positive Phase III readout.
  • After five years and more than 450,000 patients treated since its launch, Dupixent is still expanding at a good rate.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars